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* Corresponding author. Abstract: 
In its largest outbreak, Ebola virus disease is spreading through Guinea, Liberia, Sierra Leone, 
and Nigeria. We sequenced 99 Ebola virus genomes from 78 patients in Sierra Leone to 
~2,000x 
coverage.  We  observed  a  rapid  accumulation  of  interhost  and  intrahost  genetic  variation, 
allowing us to characterize patterns of viral transmission over the initial weeks of the epidemic. 
This West African variant likely diverged from Middle African lineages 
~2004, crossed from 
Guinea to Sierra Leone in May 2014, and has exhibited sustained human-to-human transmission 
subsequently, with no evidence of additional zoonotic sources. Since many of the mutations alter 
protein sequences and other biologically meaningful targets, they should be monitored for impact 
on diagnostics, vaccines, and therapies critical to outbreak response. 
Main Text: 
Ebola virus (EBOV; formerly Zaire ebolavirus), one of five ebolaviruses, is a lethal human 
pathogen, causing Ebola virus disease (EVD) with an average case fatality rate of 78% (1). 
Previous EVD outbreaks were confined to remote regions of Middle Africa; the largest, in 1976, 
had 318 cases (2) (Fig. 1A). The current outbreak started in February 2014 in Guinea, West 
Africa (3) and spread into Liberia in March, Sierra Leone in May, and Nigeria in late July. It is 
the largest known EVD outbreak and is expanding exponentially with a doubling period of 34.8 
days (Fig. 1B). As of August 19th, 2,240 cases and 1,229 deaths have been documented (4, 5). 
Its  emergence  in  the  major  cities  of  Conakry  (Guinea),  Freetown  (Sierra  Leone),  Monrovia 
(Liberia),  and  Lagos  (Nigeria)  raises  the  specter  of  increasing  local  and  international 
dissemination. 
 
In  an  ongoing  public  health  crisis,  where  accurate  and  timely  information  is  crucial,  new 
genomic technologies can provide near real-time insights into the pathogen’s origin, transmission 
dynamics, and evolution. We used massively parallel viral sequencing to understand how and 
when  EBOV  entered  human  populations  in  the  2014  West  African  outbreak,  whether  the 
outbreak is continuing to be fed by new transmissions from its natural reservoir, and how the 
virus changed, both before and after its recent jump to humans. 
 
In  March  2014,  Kenema  Government  Hospital  (KGH)  established  EBOV  surveillance  in 
Kenema,  Sierra  Leone,  near  the  origin  of  the  2014  outbreak  (Figs.  1C,  S1)  (6).  Following 
standards  for  field-based  tests  in  previous  (7)  and  current  (3)  outbreaks,  KGH  performed 
conventional PCR-based EBOV diagnostics (8) (Fig. S2); all tests were negative through early 
May. On May 25, KGH scientists confirmed the first case of EVD in Sierra Leone. Investigation 
by the Ministry of Health and Sanitation (MoHS) uncovered an epidemiological link between 
this case and the burial of a traditional healer who had treated EVD patients in Guinea. Tracing 
led to 13 additional cases—all females who attended the burial. We obtained ethical approval 
from MoHS, the Sierra Leone Ethics and Scientific Review Committee, and our U.S. institutions 
to sequence patient samples in the U.S. using approved safety standards (6).  
 
We evaluated four independent library preparation methods and two sequencing platforms (9) 
(table S1) for our first batch of 15 inactivated EVD samples from 12 patients. Nextera library 
construction and Illumina sequencing provided the most complete genome assembly and reliable 
intrahost single nucleotide variant (iSNV, frequency >0.5%) identification (6). We used this 
combination  for  a  second  batch  of  84  samples  from  66  additional  patients,  performing  two 
independent  replicates  from  each  sample  (Fig.  1D).  We  also  sequenced  35  samples  from suspected EVD cases that tested negative for EBOV; genomic analysis identified other known 
pathogens, including Lassa virus, HIV-1, enterovirus A and malaria parasites (Fig. S3).  
 
In  total,  we  generated  99  EBOV  genome  sequences  from  78  confirmed  EVD  patients, 
representing over 70% of the EVD patients diagnosed in Sierra Leone in late May to mid June; 
we  employed  multiple  extraction  methods  or  timepoints  for  13  patients  (table  S2).  Median 
coverage was >2,000x, spanning more than 99.9% of EBOV coding regions (Fig. 1D,E, table 
S2). 
 
We  combined  the  78  Sierra  Leonean  sequences  with  3  published  Guinean  samples  (3) 
(correcting 21 likely sequencing errors in the latter (6)) to obtain a dataset of 81 sequences. They 
reveal 341 fixed substitutions between the 2014 EBOV and all previously published EBOV (35 
nonsynonymous,  173  synonymous,  133  noncoding),  with  an  additional  55  single  nucleotide 
polymorphisms (SNPs) (fixed within individual patients) within the West African outbreak (15 
nonsynonymous, 25 synonymous, 15 noncoding). Notably, the Sierra Leonean genomes differ 
from PCR probes for five separate assays used for EBOV and pan-filovirus diagnostics (table 
S3). 
 
Deep-sequence  coverage  allowed  identification  of  263  iSNVs  (73  nonsynonymous,  108 
synonymous, 70 noncoding, and 12 frameshift) in the Sierra Leone patients (6). For all patients 
with multiple time points, consensus sequences were identical and iSNV frequencies remained 
stable (Fig. S4). One notable intrahost variation is the RNA editing site of the glycoprotein (GP) 
gene (Fig. S5A) (10-12), which we characterize in patients (6). 
 
Phylogenetic  comparison  to  all  20  genomes  from  earlier  outbreaks  suggests  the  2014  West 
African virus likely spread from Middle Africa within the last decade. Rooting the phylogeny 
using divergence to other ebolavirus genomes is problematic (Figs. 2A, S6) (6, 13). However, 
rooting the tree on the oldest outbreak reveals a strong correlation between sample date and root-
to-tip distance, with a substitution rate of 8x10
-4/site/year (Figs. 2B, S7) (13). This suggests that 
the lineages of the three most recent outbreaks all diverged from a common ancestor at roughly 
the same time c. 2004 (Fig. 2C, 3A), supporting the hypothesis that each outbreak represents an 
independent  zoonotic  event  from  the  same  genetically  diverse  viral  population  in  its  natural 
reservoir.  
 
Genetic similarity across the sequenced 2014 samples suggests a single transmission from the 
natural  reservoir,  followed  by  human-to-human  transmission  during  the  outbreak.  Molecular 
dating places the common ancestor of all sequenced Guinea and Sierra Leone lineages around 
late February 2014 (Fig. 3B), three months after the earliest suspected cases in Guinea (3); this 
coalescence would be unlikely had there been multiple transmissions from the natural reservoir. 
Thus, in contrast to some previous EVD outbreaks (14), continued human-reservoir exposure is 
unlikely to have contributed to the growth of this epidemic in areas represented by available 
sequence data. 
 
Our data suggest the Sierra Leone outbreak stemmed from the introduction of two genetically 
distinct viruses from Guinea around the same time. Samples from 12 of the first EVD patients in 
Sierra Leone, all believed to have attended the funeral of an EVD case from Guinea, fall into two 
distinct clusters (clusters 1 and 2) (Figs. 4A, S8). Molecular dating places the divergence of these two lineages in late April (Fig. 3B), pre-dating their co-appearance in Sierra Leone in late May 
(Fig.  4B),  suggesting  the  funeral  attendees  were  most  likely  infected  by  two  lineages  then 
circulating in Guinea, possibly at the funeral (Fig. S9). All subsequent diversity in Sierra Leone 
accumulated on the background of those two lineages (Fig. 4A), consistent with epidemiological 
information from tracing contacts. 
  
Patterns  in  observed  intrahost  and  interhost  variation  provide  important  insights  about 
transmission and epidemiology. Groups of patients with identical viruses or with shared intrahost 
variation show temporal patterns suggesting transmission links (fig. S10). One iSNV (position 
10,218) shared by twelve patients is later observed as fixed within 38 patients, becoming the 
majority allele in the population (Fig. 4C) and defining a third Sierra Leone cluster (Figs. 4A, 
4D, S8). Repeated propagation at intermediate frequency suggests that transmission of multiple 
viral haplotypes may be common. Geographic, temporal, and epidemiological metadata supports 
the transmission clustering inferred from genetic data (Figs. 4D, 4E, S11) (6). 
 
The observed substitution rate is roughly twice as high within the 2014 outbreak as between 
outbreaks (Fig. 4F). Mutations are also more frequently nonsynonymous during the outbreak 
(Fig. 4G). Similar findings have been seen previously (15) and are consistent with expectations 
from  incomplete  purifying  selection  (16-18).  Determining  whether  individual  mutations  are 
deleterious,  or  even  adaptive,  would  require  functional  analysis;  however,  the  rate  of 
nonsynonymous mutations suggests that continued progression of this epidemic could afford an 
opportunity for viral adaptation (Fig. 4H), underscoring the need for rapid containment. 
 
As in every EVD outbreak, the 2014 EBOV variant carries a number of genetic changes distinct 
to this lineage; our data do not address whether these differences are related to the severity of the 
outbreak. However, the catalog of 395 mutations, including 50 fixed nonsynonymous changes 
with 8 at positions with high levels of conservation across ebolaviruses, provide a starting point 
for such studies (table S4). 
 
To aid in relief efforts and facilitate rapid global research, we immediately released all sequence 
data as generated. Ongoing epidemiological and genomic surveillance is imperative to identify 
viral  determinants  of  transmission  dynamics,  monitor  viral  changes  and  adaptation,  ensure 
accurate diagnosis, guide research on therapeutic targets, and refine public-health strategies. It is 
our hope that this work will aid the multidisciplinary, international efforts to understand and 
contain this expanding epidemic.   References and Notes: 
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   Fig. 1. Ebola outbreaks, historical and current. (A) Historical EVD outbreaks, colored by 
decade. Circle area represents total number of cases (RC = Republic of the Congo; DRC = 
Democratic Republic of Congo). (B) 2014 outbreak growth (confirmed, probable and suspected 
cases). (C) Spread of EVD in Sierra Leone by district. The gradient denotes number of cases and 
the arrows depict likely direction. (D) EBOV samples from 78 patients were sequenced in two 
batches, totaling 99 viral genomes (Replication = technical replicates (6)). Mean coverage and 
median  depth  of  coverage  with  range  are  shown.  (E)  Combined  normalized  (to  the  sample 
average) coverage across sequenced EBOV genomes. 
 
   Fig. 2. Relationship between outbreaks. (A) Unrooted phylogenetic tree of EBOV samples; 
each major clade corresponds to a distinct outbreak (scale bar = nucleotide substitutions/site). (B) 
Root-to-tip  distance  correlates  better  with  sample  date  when  rooting  on  the  1976  branch 
(R
2=0.92, top) than on the 2014 branch (R
2=0.67, bottom). (C) Temporally rooted tree from (A). 
 
   Fig. 3. Molecular dating of the 2014 outbreak. (A) BEAST dating of the separation of the 
2014  lineage  from  Middle  African  lineages  (SL  =  Sierra  Leone;  GN  =  Guinea;  DRC  = 
Democratic Republic of Congo; tMRCA: Sep 2004, 95% HPD: Oct 2002 - May 2006). (B) 
BEAST dating of the tMRCA of the 2014 West African outbreak (tMRCA: Feb 23, 95% HPD: 
Jan 27 - Mar 14) and the tMRCA of the Sierra Leone lineages (tMRCA: Apr 23, 95% HPD: Apr 
2  -  May  13);  probability  distributions  for  both  2014  divergence  events  overlayed  below. 
Posterior support for major nodes is shown. 
 
   Fig. 4. Viral dynamics during the 2014 outbreak. (A) Mutations, one patient sample per row; 
beige = identical to Kissidougou Guinean sequence (accession KJ660346). The top row shows 
the type of mutation (green: synonymous, pink: nonsynonymous, intergenic: gray), with genomic 
locations  indicated  above.  Clusters  assignments  are  shown  on  left.  (B)  Number  of  EVD-
confirmed patients per day, colored by cluster (arrow: first appearance of the derived allele at 
position 10,218, distinguishing clusters 2 and 3). (C) Intrahost frequency of SNP 10,218 in all 78 
patients (absent in 28 patients, polymorphic in 12, fixed in 38). (D & E) 12 patients carrying 
iSNV 10,218 cluster geographically and temporally (HCW-A = unsequenced health care worker, 
Driver drove HCW-A from Kissi Teng to Jawie, then continued alone to Mambolo, HCW-B 
treated  HCW-A).  (F)  Substitution  rates  within  the  2014  outbreak  and  between  all  EVD 
outbreaks.  (G)  Proportion  of  nonsynonymous  changes  observed  on  different  time  scales 
(green=synonymous; pink=nonsynonymous). (H) Acquisition of genetic variation over time. 50 
mutational  events  (short  dashes)  and  29  new  viral  lineages  (long  dashes)  were  observed 
(intrahost variants not included). 
 